` 002422 (Sichuan Kelun Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

002422
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of 6% compared to the Shanghai Composite's 8% growth.

Stocks Performance
002422 vs Shanghai Composite

Loading
002422
Shanghai Composite
Add Stock

Performance Gap
002422 vs Shanghai Composite

Loading
002422
Shanghai Composite
Difference

Performance By Year
002422 vs Shanghai Composite

Loading
002422
Shanghai Composite
Add Stock

Competitors Performance
Sichuan Kelun Pharmaceutical Co Ltd vs Peers

Shanghai Composite
002422
LLY
JNJ
NOVO B
ROG
Add Stock

Sichuan Kelun Pharmaceutical Co Ltd
Glance View

Market Cap
51.6B CNY
Industry
Pharmaceuticals

Nestled in the vibrant economic tapestry of China, Sichuan Kelun Pharmaceutical Co., Ltd. has emerged as a formidable player in the healthcare industry. Established in the late 1990s, the company embarked on its journey with a commitment to the development and production of intravenous infusion solutions. These infusion products have become the lifeblood of Kelun's operations, offering a critical healthcare solution that serves both domestic and international markets. By leveraging advanced technology and maintaining stringent quality control, Kelun ensures its offerings meet the diverse and demanding needs of modern medical practice. The company's narrative intertwines innovation with growth, as reflected in its expansive product range that has evolved to encompass antibiotics, traditional Chinese medicine, and comprehensive research in biotechnology. But Kelun's story doesn't stop there; it stands out in the pharmaceutical landscape through its integrated business model. By investing heavily in research and development, Kelun fuels its pipeline with new drugs, ensuring a steady stream of clinically effective and market-ready products. It also navigates strategic alliances and collaborations, stitching together a network that amplifies its market penetration and operational scalability. These moves not only consolidate its standing in the healthcare sector but also streamline supply chains, thereby optimizing revenues. With an agile approach that adapts to regulatory changes and market dynamics, Sichuan Kelun Pharmaceutical continues to script a narrative of resilience and business acumen in the global arena.

Intrinsic Value
44.08 CNY
Undervaluation 27%
Intrinsic Value
Price
Back to Top